Methods for the manufacture of recombinant viral vectors

Patent metadata

Field	Value
Publication number	US-12398403-B2
Application number	US-202017598503-A
Country	US
Kind code	B2
Filing date	Mar 26, 2020
Priority date	Mar 28, 2019
Publication date	Aug 26, 2025
Grant date	Aug 26, 2025

Abstract

The present invention relates to methods for the production of high titer recombinant viral vectors, more particularly recombinant AAV vectors, so that the methods can be effectively employed on a scale that is suitable for the practical application of gene therapy techniques.

First claim

The invention claimed is:

1. A method for the production of a recombinant Adeno-Associated Virus (AAV) vector, the method comprising the steps of:
a) co-transfecting a suitable cell culture with three plasmid vectors:
i) a first plasmid vector characterized in that the plasmid backbone size is above 5000 bp, and comprising a heterologous nucleotide sequence flanked by inverted terminal repeats (ITRs) and a stuffer DNA sequence located outside said ITRs, wherein said stuffer sequence has a length between 4400 bp and 4800 bp, wherein said plasmid vector does not contain an F1Ori nucleotide sequence in the backbone sequence, and wherein said plasmid vector is pcohSqsh-900 with accession number DSM 32967 having the sequence as set forth in SEQ ID NO: 2;
ii) a second plasmid vector comprising from 5′ to 3′ an AAV rep coding region, an AAV cap coding region and a nucleotide sequence comprising a AAV p5 promoter region; and
iii) a third plasmid vector comprising adenovirus helper functions including VA-RNA, E2A and E4 sequences, wherein said plasmid does not contain E3, pTB (E2B), and Ad ITR and protease sequences, and wherein said plasmid vector is pAdHelper-861 having accession number DSM 32965 having the sequence as set forth in SEQ ID NO: 6;
b) culturing said cells under conditions allowing AAV replication and packaging;
c) recovering recombinant AAVs produced in step b) and retaining the cells in the cell culture under conditions allowing further division and growth;
d) re-transfecting the cells according to step c) with the plasmid vectors according to step a); and
e) repeating steps b) to c).

2. The method of claim 1 , wherein in step b) recombinant AAVs are secreted to the supernatant of the cell culture.

3. The method of claim 1 , wherein the cell media of the cell culture is exchanged before step d).

4. The method of claim 3 , wherein cell media exchange is performed by perfusion.

5. The method of claim 1 , wherein steps d), b) and c) are repeated at least one more time after recovering step c).

6. The method of claim 1 , wherein step b) is performed culturing said cell in suspension in agitated liquid medium.

7. A method for the production of a recombinant AAV vector the method comprising the steps of:
a) co-transfecting a suitable cell with
i) a first plasmid vector characterized in that the plasmid backbone size is above 5000 bp, and comprising a heterologous nucleotide sequence flanked by ITRs and a stuffer DNA sequence located outside said ITRs, wherein said stuffer sequence has a length between 4400 bp and 4800 bp, wherein said plasmid vector does not contain an F1Ori nucleotide sequence in the backbone sequence, and wherein said plasmid vector is pcohSgsh-900 with accession number DSM 32967 having the sequence as set forth in SEQ ID NO: 2;
ii) a second plasmid vector comprising from 5′ to 3′ an AAV rep coding region, an AAV cap coding region and a nucleotide sequence comprising an AAV p5 promoter region; and
iii) a third plasmid vector comprising adenovirus helper functions including VA-RNA, E2A and E4 sequences, wherein said plasmid does not contain E3, pTB (E2B), and Ad ITR and protease sequences, and wherein said plasmid vector is pAdHelper-861 having accession number DSM 32965 having the sequence as set forth in SEQ ID NO: 6;

b) culturing said cell under conditions allowing AAV replication and packaging; and
c) recovering recombinant AAVs produced in step b).

8. The method of claim 7 , wherein said second plasmid vector (ii) comprises AAV Rep2 and AAV Cap9 coding regions.

9. A plasmid vector comprising:
a) a heterologous nucleotide sequence flanked by inverted terminal repeats (ITRs); and
b) a stuffer DNA sequence located outside said ITRs and adjacent to one ITR, wherein said stuffer sequence has a length between 4400 bp and 4800 bp so that the plasmid backbone size is above 5 Kb;
wherein said plasmid vector does not contain an F1Ori nucleotide sequence in the backbone sequence, and wherein said plasmid vector is pcohSgsh-900 with accession number DSM 32967 having the sequence as set forth in SEQ ID NO: 2.

10. A plasmid vector comprising adenovirus helper function sequences selected from the group consisting of VA-RNA, E2A and E4 sequences, wherein said plasmid does not contain E3, pTB (E2B), and Ad ITR and protease sequences, and wherein said plasmid vector is pAdHelper-861 having accession number DSM 32965 and having the sequence as set forth in SEQ ID NO: 6.

Assignees

• Esteve Pharmaceuticals Sa
• Univ Barcelona Autonoma

Inventors

• Godia-Casablancas Francesc
• Bosch-Tubert Maria-Fàtima
• Garcia-Martinez Miguel
• Cervera-Gracia Laura
• Leon-Madrenas Xavier
• Molas-Laplana Maria
• Gutierrez-Granados Sonia

Classifications

• C12N2750/14152

  relating to complementing cells and packaging systems for producing virus or viral particles · CPC title

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• C12N7/02

  Recovery or purification · CPC title

• C12N2750/14151

  Methods of production or purification of viral material · CPC title

• C12N15/86 Primary

  Viral vectors · CPC title